Cdk5 regulates myogenesis but the signaling cascade through which Cdk5 modulates this process remains to be characterized. Here, we investigated whether PI3K, Akt, p70S6K, p38 MAPK, p44/42 MAPK, and Egr-1 serve as upstream regulators of Cdk5 during L6 myoblast differentiation. Upon serum reduction, we found that besides elevated expression of Cdk5 and its activator, p35, and increased Cdk5/p35 activity, Egr-1, Akt, p70S6K, and p38 MAPK activity were upregulated in differentiating L6 cells. However, p44/42 MAPK was downregulated and SAPK/JNK was unaffected. LY294002, a PI3K inhibitor, blocked the activation of Akt and p70S6K, indicating that Akt and p70S6K activation is linked to PI3K activation. The lack of LY294002 effect on p38 MAPK suggests that p38 MAPK activation is not associated with PI3K activation. Rapamycin, a specific inhibitor of FRAP/mTOR (the upstream kinase of p70S6K), also blocked p70S6K activation, indicating the involvement of FRAP/mTOR activation. LY294002 and rapamycin also blocked the enhancement of Egr-1 level, Cdk5 activity, and myogenin expression, suggesting that upregulation of these factors is coupled to PI3K-p70S6K activation. Overexpression of dominant-negative-Akt also reduced Cdk5/p35 activity and myogenin expression, indicating that the PI3K-p70S6K-Egr-1-Cdk5 signaling cascade is linked to Akt activation. SB2023580, a p38 MAPK inhibitor, had no effect on p70S6K, Egr-1, or Cdk5 activity, suggesting that p38 MAPK activation lies in a pathway distinct from the PI3K-Akt-p70S6K-Egr-1 pathway that we identify as the upstream modulator of Cdk5 activity during L6 myoblast differentiation.
Introduction
Cyclin-dependent kinase 5 (Cdk5) is a small serine/ threonine kinase that has close structural homology to the cell cycle Cdks (Lew and Wang, 1995) . Although Cdk5 binds cyclins such as cyclin D and cyclin E (Xiong et al., 1992; Zhang et al., 1993; Miyajima et al., 1995; Guidato et al., 1998) , there is no evidence that Cdk5 activity is regulated by these cyclins (Morgan, 1997) . Instead, activation of Cdk5 has been shown to be dependent on p35, which is distantly related to cyclins (Lee et al., 1997; Dhavan and Tsai, 2001 ). Although Cdk5 is widely expressed in mammalian tissues, its activator, p35, is generally considered to be neuron specific. However, recent studies by our group (Rosales et al., 2004) and others (Gao et al., 1997; Lazaro et al., 1997; Philpott et al., 1997; Chen and Studzinski, 2001) have implicated Cdk5 activity in other tissues. In mouse C2 myoblasts, Cdk5 level and activity have been shown to increase during early myogenesis (Lazaro et al., 1997) . Plasmids encoding wild-type (wt) Cdk5 enhances C2 myoblast differentiation as evidenced by increased myogenin and troponin T expression while dominantnegative-Cdk5 (dn-Cdk5) inhibits the onset of differentiation. Furthermore, in Xenopus embryo, expression of dn-Cdk5 results in disruption of somatic muscle patterning and suppression of the expression of the myogenesis regulators, MYOD and MRF4 (Philpott et al., 1997) . These observations indicate that Cdk5 is a regulator of myoblast differentiation.
Although an increasing line of evidence demonstrates the significance of Cdk5 in myogenesis, no study has yet been dedicated to investigate the upstream signaling pathway through which Cdk5 is activated during muscle differentiation. The PI3K and its downstream signaling molecules have been implicated in insulin/insulin-like growth factor I (IGF-I)-induced myoblast differentiation. For example, activation of PI3K (Tureckova et al., 2001; Conejo et al., 2002; Laprise et al., 2002) , Akt (Tamir and Bengal, 2000) , p70S6K (Conejo et al., 2002) , p38 MAPK (Conejo et al., 2002) , and p44/42 MAPK (Gredinger et al., 1998; Ostrovsky and Bengal, 2003) has been found during muscle differentiation. On the other hand, the expression of Egr-1, which is also functionally involved in cell differentiation (Cao et al., 1990; Liu et al., 1991) , has been shown to increase through PI3K activity (Harada et al., 2001b) . Previously, it has been reported that Egr-1 mediates the induction of p35 (Harada et al., 2001a) , a Cdk5 activator protein.
In the present study, we sought to characterize the signaling pathway leading to Cdk5 activation during myoblast differentiation. We identify the PI3K-Akt-p70S6K-Egr-1 signaling cascade as the upstream pathway through which Cdk5 modulates differentiation of L6 myoblasts.
Results
Cdk5, Akt, and p70S6K are activated during L6 myoblast differentiation
In proliferating myoblasts, muscle-specific proteins and their mRNAs are either absent or present in very low concentrations (Kitzmann and Fernandez, 2001) . When cultured in differentiation media, myoblasts stop dividing and muscle-specific genes are expressed. In accord with the findings of Arnold et al. (1992) , myogenin expression in L6 myoblasts was evident as early as 36 h, and peaked between 48 and 72 h after switching to differentiation media (DM, 2% FBS; data not shown). In addition, consistent with a previous study suggesting that Cdk5 activity positively correlates with myogenesis (Lazaro et al., 1997) , we found that Cdk5/p35 activity begin to increase 24 h after inducing differentiation of L6 cells, and a considerable increase in kinase activity was noted at 36 and 48 h (Figure 1a ). This observation was accompanied by an increase in both p35 (Figure 2b, upper panel) and Cdk5 (Figure 2b , middle panel) levels. The loss of Cdk5 activity 96 h after inducing differentiation coincides with a decrease in p35 level.
As stress and survival signaling pathways are often simultaneously activated in response to growth factor withdrawal, we investigated whether the major stress signaling molecule, JNK, is activated in differentiating L6 cells. As shown in Figure 1c , JNK is not activated in these cells, indicating that low serum has mainly activated the signaling molecules for differentiation rather than those for stress/survival. In accord with this finding, viability of cells at 48 h following exposure to DM is comparable to cells maintained in culture media ( Figure 1d ).
To identify the upstream signaling molecules that regulate Cdk5 activity during L6 myoblast differentiation, we initially examined the activation of Akt, a downstream signaling molecule of PI3K (Datta et al., 1996) , following induction of L6 myoblast differentiation. Figure 2a (upper panel) shows a remarkable increase in serine 473 phosphorylation on Akt 20 min after switching to DM. The increase in phosphorylation was sustained for 3 h following exposure to DM. Since p70S6K, another downstream signaling molecule of PI3K, has been reported to be activated during differentiation of many cell types, we also examined whether p70S6K was activated during L6 differentiation by analysing its level of phosphorylation at threonine 389, which is thought to be one of its crucial phosphorylation sites for activity (Han et al., 1995) . As shown in Figure 2b (upper panel), phosphorylation at threonine 389 was somewhat increased at 20 min but peaked 1 h after inducing differentiation.
p38 MAPK but not p44/42 MAPK is activated in differentiating L6 cells
We then tested whether the signaling pathway leading to Cdk5 activation during L6 myoblast differentiation involves the p38 MAPK or the p44/42 MAPK. We noted that p38 MAPK was activated between 7 min and 24 h following serum reduction (Figure 3a, upper panel) . In contrast, p44/42 MAPK activity appears to decrease after inducing differentiation, but activity is sustained even at 96 h after serum reduction ( Figure 3b , upper panel).
LY294002 inhibits activation of Akt and p70S6K but not p38 MAPK
To determine whether activation of Akt, p70S6K, and p38 MAPK was dependent on PI3K activity, L6 cells Akt and p70S6K are activated during L6 myoblast differentiation. Phosphorylation of (a) Akt at serine 473 and (b) p70S6K at threonine 389 was examined in L6 cells maintained in DM at the indicated time points. Blots were initially probed with phosphorylation-independent antibodies (lower panels) and reprobed with the phospho-specific antibodies (upper panels) to detect activation PI3K-AKT-p70S6K and Cdk5 signaling during myoblast differentiation KP Sarker and K-Y Lee were incubated in DM with LY294002, a phenolic compound that inhibits the activation of PI3K by binding to its ATP-binding domain (Agullo et al., 1997; Davies et al., 2000) . We found that LY294002 blocked the activation of Akt ( Figure 4a ) and p70S6K ( Figure 4b ) but not p38 MAPK (Figure 4c ). These findings indicate that Akt and p70S6K activation during serum reduction-induced L6 differentiation is linked to PI3K activation. However, the lack of LY294002 effect on p38 MAPK at different time points after inducing differentiation ( Figure 4c ) suggests that p38 MAPK activation is not associated with PI3K activation. The observation that rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), which is an upstream kinase of p70S6K, blocked the phosphorylation of threonine 389 on p70S6K (Figure 4b ) further suggests that p70S6K activation is associated with PI3K-mTOR signaling. On the other hand, the lack of effect on p70S6K phosphorylation upon treatment with SB203580 (Figure 4b ), a specific and potent inhibitor of p38 MAPK, supports the suggestion that p38 MAPK activation is not linked to PI3K-p70S6K activation during L6 differentiation.
Egr-1 is upregulated in differentiating L6 cells
Since cell differentiation has also been associated with induction of Egr-1 (Cao et al., 1990; Liu et al., 1991) , which upregulates the expression of the Cdk5 activator, p35 (Harada et al., 2001b) , we examined the level of Egr-1 in L6 cells exposed to DM. As shown in Figure 5a , Egr-1 level noticeably increased 4 h after serum reduction and a significant level remained 6 h after inducing differentiation. To determine whether this Egr-1 upregulation is related to PI3K-p70S6K or p38 MAPK signaling, L6 cells were incubated in DM with LY294002, rapamycin, or SB203580. As shown in Figure 5b , LY294002 and rapamycin inhibited Egr-1 expression while SB203580 had no effect, suggesting that Egr-1 upregulation is linked to PI3K-p70S6K activation but not p38 MAPK activation.
The PI3K-Akt-p70S6K signaling cascade regulates Cdk5 activity during L6 differentiation To determine whether PI3K, Akt, p70S6K, and p38 MAPK activation is linked to Cdk5 activation during L6 myoblast differentiation, we first tested whether inhibition of PI3K, p70S6K, or p38 MAPK affects Cdk5 activity in differentiating L6 cells. As shown in Figure 6a , LY294002 and rapamycin significantly inhibited Cdk5 activity, and a combination of LY294002 and rapamycin completely abolished the kinase's activity. However, SB203580 had no significant effect. As shown in Figure 6a (lower panel), Cdk5 activity correlated with levels of Cdk5 in p35 immunoprecipitates. These findings suggest that Cdk5 activation during L6 differentiation is coupled to PI3K-p70S6K activation. When L6 cells were transfected with dn-Akt, we noted a significant decrease in Cdk5 activity (Figure 6b) , and again, Cdk5 activity correlated with levels of Cdk5 in p35 immunoprecipitates (Figure 7b, lower panel) . These observations indicate that the PI3K-p70S6K-Cdk5 signaling cascade is also linked to Akt. Consistent with these findings, we observed that inhibition of PI3K, Akt, or p70S6K activity with LY294002, dn-Akt, or rapamycin, respectively, caused a significant decrease in L6 cell expression of p35 (Figure 6c ) and myogenin (Figure 6d ), a muscle-specific protein that plays a key role in myoblast differentiation. The decrease in p35 
Discussion
Cdk5 has been determined to be a key player in muscle differentiation (Lazaro et al., 1997; Philpott et al., 1997 ), but it is not known how Cdk5 activity is upregulated during this process. There have also been evidence that activation of PI3K, Akt, p70S6K, p38 MAPK, and p44/ 42 MAPK is involved in muscle differentiation (Gredinger et al., 1998; Tamir and Bengal, 2000; Conejo et al., 2002) . However, no link between Cdk5 and these molecules has been described in myogenesis. Therefore, we investigated the possibility that PI3K and its signaling molecules modulate Cdk5 activity during L6 myoblast differentiation. The activation of PI3K and Akt during serum reduction-induced L6 myoblast differentiation concur with previous observations in other differentiating myoblast cell lines (Tamir and Bengal, 2000; Tureckova et al., 2001; Laprise et al., 2002) . For example, in C2C12 myoblasts, it has been shown that overexpression of constitutively active Akt induces myotube formation (Rommel et al., 1999) . Furthermore, Conejo et al. (2002) have shown a positive link between activation of Akt and C2C12 myoblast differentiation. Although Akt can be activated by a PI3K-independent mechanism such as in response to heat shock or increases in intracellular Ca 2 þ (Konishi et al., 1996; Moule et al., 1997; Sable Figure 7 Proposed model for the signaling cascade leading to Cdk5 activation during L6 myoblast differentiation. We propose a model whereby activation of PI3K during serum reduction causes Akt and p70S6K activation via PDK1 and FRAP/mTOR, respectively. This is followed by Egr-1 upregulation, which causes increased p35 expression and consequently, increased Cdk5 activation. During L6 cell differentiation, a distinct pathway involving p38 MAPK is activated as well et al., 1997), inhibition of Akt activity by LY294002 during L6 differentiation suggests that Akt activation during the process is dependent on PI3K. On the other hand, the sensitivity of p70S6K phosphorylation at threonine 389 to PI3K inhibition suggests a link between PI3K activation and p70S6K activation during L6 myoblast differentiation. This is consistent with the finding in other cell types that, in the absence of extracellular signals, p70S6K is activated by constitutively active mutants of PI3K (Chung et al., 1994; Reif et al., 1997) . The fact that the FRAP inhibitor, rapamycin, also blocks the activation of p70S6K during L6 myoblast differentiation further supports the notion that p70S6K activation during L6 differentiation occurs in a PI3K/FRAP-dependent manner. Activation of p38 MAPK has been observed in the early phase (Conejo et al., 2002) while activation of p44/ 42 MAPK in the later phase (Gredinger et al., 1998; Ostrovsky and Bengal, 2003) of C2C12 myoblast differentiation. Although activation of p38 MAPK has been linked to PI3K activation in IGF-1-induced C2C12 myoblast differentiation (Conejo et al., 2002) , our data indicate that p38 MAPK activation during low seruminduced L6 myoblast differentiation is not associated with PI3K activation. In addition, p38 MAPK does not act as a downstream effector of PI3K during L6 myoblast differentiation. Thus, it appears that a PI3K-Akt-p70S6K-dependent pathway and a PI3K-independent p38 MAPK pathway are involved in the early stage of L6 differentiation.
The role of ERK (p44/42 MAPK) in muscle differentiation has been controversial. For example, Lechner et al. (1996) and Zetser et al. (2001) have shown that ERK is a positive regulator of muscle differentiation. On the other hand, Jones et al. (2001) , Rommel et al. (1999) , and Winter and Arnold (2000) have reported that ERK is part of a Raf-1-MEK signaling pathway that inhibits muscle differentiation. Here, contrary to previous findings in C2C12 cells (Gredinger et al., 1998; Ostrovsky and Bengal, 2003) , we did not find increased activation of p44/42 MAPK during L6 cell differentiation. Instead, we noted that p44/42 MAPK activation decreases during L6 differentiation, but a considerable and sustained amount of p44/42 MAPK activity remains even at 96 h postserum reduction. It is possible that such event results from a crosstalk between the Akt and ERK signaling pathways. In fact, it has been documented that Akt inhibits ERK activation through Raf-1 phosphorylation at serine 259 (Rommel et al., 1999; Reusch et al., 2001) . Our result seems to concur with the observation that inhibition of p44/42 MAPK (ERK) activity results in the enhancement of the myogenic process (Coolican et al., 1997) . However, the sustained p44/42 MAPK activation during L6 differentiation may have also contributed to the induction of Egr-1 level in differentiating L6 cells. This theory is consistent with the report of Harada et al. (2001b) that ERK induces Egr1.
As a consequence of Egr-1 induction by ERK, p35 expression is induced, resulting in the activation of Cdk5 (Harada et al., 2001b) . During L6 differentiation, we found that increase in Egr-1 expression can be inhibited by inhibition of PI3K, which also inhibits Cdk5 activity, suggesting that Egr-1 and Cdk5 lie downstream of the PI3K signaling pathway during L6 myoblast differentiation. On the other hand, the lack of effect of p38 MAPK inhibition on Egr-1 and Cdk5 activity further suggests that p38 MAPK activation during L6 differentiation lies in a pathway distinct from the PI3K-Akt-p70S6K-Egr-1-Cdk5 pathway that regulates myogenin expression during L6 myoblast differentiation.
Thus, we propose a simplified model through which Cdk5 activity is regulated during L6 myoblast differentiation. The model, which concurs with our current findings and those of others, includes the premise that serum reduction triggers the activation of PI3K, which causes Akt and p70S6K activation via PDK1 (Scheid et al., 2002) and FRAP/mTOR (Kim et al., 2000) , respectively. Egr-1 is then upregulated causing the induction of p35 expression (Harada et al., 2001b) and consequently, increased activation of Cdk5. A PI3K-independent p38 MAPK pathway is activated parallel to the activation of the PI3K-Akt-p70S6K-Egr-1-Cdk5 pathway. Although not examined in this study, the p38 MAPK activation, which seems to occur during the early stage of L6 differentiation, possibly involves MEK3/6 and MEF2 activation.
Materials and methods

Materials
LY294002 and rapamycin were from Cell Signaling Technology (Beverly, MA, USA). p38 MAPK inhibitor SB203580 was from Calbiochem (San Diego, CA, USA). The protease inhibitors leupeptin, aprotonin, and antipain, and other chemicals were from Sigma Chemicals Co (St Louis, MO, USA). The pcDNA3 constructs expressing wt, dn, and constitutively active forms of Akt were kindly provided by Dr Jim Woodgett (University of Toronto).
Antibodies
Antibodies against Akt/phos-Akt (serine 473) and p70S6K/ phospho-p70S6K (threonine 389), and MAPK assay kits (containing polyclonal antibodies against p38 MAPK, p44/42 MAPK, phospho-p38 MAPK, phospho-JNK, and phosphop44/p42 MAPK) were from Cell Signaling Technology Inc. (Beverly, MA, USA). Antibodies to Cdk5 (C-8 and DC-17), p35 (C-19), Egr-1, and myogenin were from Santa Cruz Biotech. Inc. (Santa Cruz, CA, USA). The HRP-conjugated secondary antibodies were from Zymed (San Francisco, CA, USA), and the Cy3-conjugated secondary antibody was from Sigma Chemicals Co.
Cell culture
Rat myoblast (L6) cells were cultured in DMEM high glucose media (Gibco BRL, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS) plus appropriate antibiotics at 371C in the presence of 95% air and 5% CO 2 . To induce differentiation, L6 cells grown to subconfluence were switched to media containing 2% FBS. Differentiation was assessed by examining for myogenin expression and myotube formation.
Cell viability
Cell viability was assessed by fluorescence-activated cellsorting (FACS) analysis. At the end of treatment, total cells (floating and adherent) were harvested and pelleted by centrifugation (200 g). Cells were fixed in 70% ethanol for 20 min at À201C. Cells were then incubated with propidium iodide (PI) (10 mg/ml) and RNase (5 mg/ml) for 20 min. Cell viability was evaluated by counting PI-negative cells, using a FACS-can analyzer (EPICS, Coulter).
Transfection
Transfection of L6 cells with wt-or dn-AKT, or corresponding empty vector was performed using Lipofectamine 2000 (Life Tech. Inc., Rockville, MD, USA) according to the manufacturer's instructions. At 24 h following transfection, cells were switched to differentiation media and myogenin expression was monitored at the indicated time points.
Preparation of cell lysates and Western blotting
Preparation of cell lysates and activation of MAP kinases were analysed as we described previously (Sarker et al., 2000 (Sarker et al., , 2003 . Briefly, after treatment, cells were rinsed with phosphatebuffered saline (PBS) followed by lysis using SDS sample buffer. Proteins were resolved in 12.5% SDS-PAGE, transferred onto a nitrocellulose membrane, and probed with the appropriate antibody. Immunoreactive proteins were visualized using the ECL kit (Amersham Pharmacia Biotech. Inc., Piscataway, NJ, USA).
Immunostaining L6 myoblast cells seeded onto glass coverslips were pretreated with inhibitors or transfected with vectors then switched to differentiation media. At the end of the designated time point, cells were rinsed with PBS, incubated with 4% paraformaldehyde in PBS for 15 min, washed, and permeabilized with 0.25% Triton X-100 for 10 min. This was followed by incubation with the myogenin antibody (1 : 100 dilution) for 30 min at RT, and the Cy3-conjugated secondary antibody for 30 min. Incubation with DAPI was performed to stain nuclei. The fluorescent images were visualized using an Olympus 1X71 inverted microscope.
In vitro kinase assay
At 24 h after transfection with pcDNA expressing wt-or dnAkt, cells were exposed to differentiation media for the indicated time period. Following treatment, cells were lysed in lysis buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 1 mM DTT, 1 mM PMSF), and kinase assay of p35 immunoprecipitates was carried out as we described previously (Lee et al., 1996) .
